Authors: M. Průcha; R. Zazula; B. Kavka; J. Hyánek Authors‘ workplace: Oddělení klinické biochemie, hematologie a imunologie, Nemocnice Na Homolce, Praha, primář prof. MUDr. Josef Hyánek, DrSc. Klinika anesteziologie a resuscitační péče, IKEM, Praha, primář MUDr. Roman Zazula Oddělení anesteziologie a resuscitační péče, Nemo Published in: Anest. intenziv. Med., , 2001, č. 6, s. 320-323 Category:
Immunoparalysis is a relatively frequent finding in critically ill patients treated in the i ntensive care unit. It is characterized by reduced monocyteHLA-DR expression below 30% and decreased production of tumor necrosis factor-a after stimulation with lipopolysaccharid ex vivo lower than 300pg/ml. For the function of the immune system it means inadequate antigen presentation with subsequent defect in the nonspecific and specific immuneresponse. It means also inadequate activity of the proinflammatory reactions which provide homeostasis. In this situation there is a prevalence of theantiinflammatory processes associated with adverse clinical prognosis. For the differentiation between infectious and noninfectious inflammation weuse the level of procalcitonin and granulocyte CD64 expression. Immunoparalysis does not necessarily imply that infection is present, it can be alsocaused by the cytokines. The diagnosis of immunoparalysis helps us distinguish patients who are on the opposite sides of the function of the immunesystem – the patients with high production of the proinflammatory cytokines and the patients with a prevalence of the antiinflammatory response. Thisis starting point for immunomodulatory therapy in these patients.
Key words: immunoparalysis – HLA-DR/CR14 – production of tumor necrosis factor – procalcitonin – immunomodulation
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
